Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00329108
Status:
TERMINATED
Last Update Posted:
2021-03-29
First Post:
2006-05-05
Brief Title:
Ziprasidone And Olanzapines Outcomes In Mania
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Parallel Group Study Comparing The Efficacy And Tolerability Of Ziprasidone Zeldox Geodon vs Olanzapine Zyprexa In The Treatment And Maintenance Of Response In Patients With Acute Mania
Status:
TERMINATED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Please see Brief Summary for Termination Reason
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ZOOM
Brief Summary:
The purpose of this study is to compare the efficacy and tolerability of ziprasidone versus olanzapine in the treatment of acute mania An open label extension will further evaluate the efficacy safety and tolerability of ziprasidone compared with olanzapine Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on July 30 2007 Subjects that were enrolled at the time completed the study as per protocol There were no safety concerns involved in the decision to stop enrollment The Last Subject Last Visit was January 10 2008
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None